Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $30.93M by Medicaid between Jan 2018 and Dec 2024, across 228 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
BROOKLYN, NY 11207
BROOKLYN, NY 11207
33aNPI1063577831assigned 12/22/2006
33bProvider typeInternal Medicine Physician
28Total paid$30.93M
24GClaims812,160
24DCodes billed228
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#13 of 6,049
Median peer was paid$11K
This provider vs. median2,735×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,113 | $570K | |
| 2019 | 29,093 | $1.15M | |
| 2020 | 131,553 | $5.37M | |
| 2021 | 270,327 | $10.23M | |
| 2022 | 132,325 | $5.35M | |
| 2023 | 109,714 | $4.29M | |
| 2024incomplete | 116,035 | $3.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 15% | 63,992 | 53,981 | $4.71M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 52,108 | 42,311 | $4.15M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.7% | 34,263 | 28,703 | $2.38M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 6.9% | 22,748 | 15,598 | $2.12M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.9% | 17,949 | 15,246 | $1.84M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.7% | 59,233 | 50,856 | $1.14M |
| 36415 | Collection of venous blood by venipuncture | 3.4% | 120,047 | 35,787 | $1.05M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.8% | 7,035 | 4,588 | $861K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.3% | 7,207 | 6,640 | $722K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.9% | 5,535 | 5,183 | $602K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.9% | 24,442 | 21,369 | $582K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.6% | 5,373 | 4,802 | $490K |
216 more codes
| 99442 | 1.3% | 5,385 | $416K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 9,935 | $390K |
| 99443 | 1.2% | 4,196 | $384K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.2% | 4,508 | $381K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.2% | 11,190 | $363K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.1% | 3,627 | $329K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 10,118 | $317K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.0% | 16,833 | $315K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.0% | 8,489 | $312K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,858 | $294K |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 1,803 | $288K |
| 86480 | <1% | 4,612 | $285K | |
| 99441 | <1% | 4,412 | $261K | |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 1,794 | $254K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,903 | $249K |
| 80061 | Lipid panel | <1% | 19,412 | $224K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,820 | $214K |
| 99201 | <1% | 2,443 | $194K | |
| 80053 | Comprehensive metabolic panel | <1% | 15,032 | $177K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,137 | $169K |
| 90461 | <1% | 3,113 | $165K | |
| 90750 | <1% | 970 | $162K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,022 | $158K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,196 | $145K |
| 85027 | <1% | 24,582 | $133K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,316 | $132K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,106 | $131K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 788 | $127K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 5,406 | $125K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 3,420 | $123K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,416 | $116K |
| 86703 | <1% | 7,931 | $105K | |
| 81001 | <1% | 21,927 | $102K | |
| 86780 | <1% | 6,767 | $87K | |
| 90651 | <1% | 1,789 | $86K | |
| 86769 | <1% | 2,881 | $84K | |
| 87536 | <1% | 907 | $84K | |
| 0012A | <1% | 2,135 | $82K | |
| 99383 | <1% | 641 | $80K | |
| 0011A | <1% | 2,252 | $74K | |
| 90686 | <1% | 6,493 | $73K | |
| 83655 | <1% | 5,439 | $71K | |
| 90677 | <1% | 411 | $70K | |
| H0040 | Assertive community treatment program, per diem | <1% | 37 | $67K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,411 | $59K |
| 86803 | <1% | 4,664 | $58K | |
| G0511 | Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month | <1% | 994 | $57K |
| D1110 | Prophylaxis - adult | <1% | 2,223 | $56K |
| 99384 | <1% | 388 | $53K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,042 | $53K |
| 90746 | <1% | 799 | $51K | |
| 96127 | <1% | 8,435 | $50K | |
| 11721 | <1% | 1,406 | $49K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,869 | $46K |
| 99051 | <1% | 2,152 | $45K | |
| 90620 | <1% | 1,054 | $45K | |
| 90715 | <1% | 1,929 | $45K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 615 | $45K |
| G0470 | Federally qualified health center (fqhc) visit, mental health, established patient; a medically-necessary, face-to-face mental health encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a mental health visit | <1% | 2,657 | $44K |
| D0120 | Dental checkup, returning patient | <1% | 2,547 | $40K |
| 86706 | <1% | 3,496 | $35K | |
| 0064A | <1% | 858 | $35K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 253 | $34K |
| 99385 | <1% | 255 | $33K | |
| 87340 | <1% | 2,995 | $30K | |
| 86762 | <1% | 2,113 | $30K | |
| 83020 | <1% | 2,219 | $29K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 1,561 | $29K |
| 86765 | <1% | 2,115 | $27K | |
| 3074F | <1% | 8,475 | $24K | |
| 86735 | <1% | 2,075 | $23K | |
| 86787 | <1% | 2,080 | $23K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 730 | $22K |
| 92250 | <1% | 498 | $22K | |
| 90670 | <1% | 878 | $21K | |
| 90734 | <1% | 1,228 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,432 | $20K |
| D0330 | Panoramic radiographic image | <1% | 1,082 | $19K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 343 | $18K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 333 | $18K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 851 | $18K |
| 82607 | <1% | 1,299 | $17K | |
| 84153 | <1% | 1,094 | $17K | |
| 99382 | <1% | 129 | $16K | |
| 90697 | <1% | 126 | $16K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 680 | $16K |
| 82728 | <1% | 1,236 | $16K | |
| 84439 | <1% | 1,991 | $16K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 544 | $16K |
| 90480 | <1% | 323 | $15K | |
| G0467 | Community health center visit, returning patient | <1% | 2,014 | $15K |
| 99386 | <1% | 96 | $14K | |
| 82274 | <1% | 1,252 | $14K | |
| D1120 | Dental cleaning, child | <1% | 821 | $14K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 408 | $14K |
| 80076 | <1% | 1,595 | $14K | |
| 82043 | <1% | 2,587 | $14K | |
| 90716 | <1% | 250 | $12K | |
| 90732 | <1% | 112 | $11K | |
| 97802 | <1% | 383 | $11K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 51 | $11K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 121 | $10K |
| 99205 | Prolong outpt/office vis | <1% | 67 | $10K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,472 | $8K |
| 0134A | <1% | 198 | $8K | |
| 81025 | <1% | 1,243 | $8K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 87 | $8K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 316 | $8K |
| 83540 | <1% | 1,240 | $7K | |
| 86704 | <1% | 665 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 958 | $7K |
| D0274 | Bitewings - four radiographic images | <1% | 759 | $7K |
| 90707 | <1% | 158 | $7K | |
| 87486 | <1% | 280 | $6K | |
| 00120 | <1% | 246 | $6K | |
| V5008 | Hearing screening | <1% | 119 | $6K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 53 | $6K |
| 90656 | <1% | 600 | $6K | |
| 87081 | <1% | 759 | $6K | |
| 86003 | <1% | 123 | $6K | |
| 90633 | <1% | 793 | $6K | |
| 86696 | <1% | 353 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 712 | $5K |
| 84466 | <1% | 406 | $5K | |
| 83550 | <1% | 668 | $5K | |
| 90669 | <1% | 583 | $5K | |
| 96161 | <1% | 482 | $5K | |
| 86695 | <1% | 352 | $5K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 81 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 52 | $4K |
| 92134 | <1% | 84 | $4K | |
| 86360 | <1% | 73 | $4K | |
| 36410 | <1% | 310 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 184 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 106 | $3K |
| 91322 | <1% | 73 | $3K | |
| 88142 | <1% | 135 | $3K | |
| 86359 | <1% | 72 | $3K | |
| 87071 | <1% | 120 | $3K | |
| 0124A | <1% | 54 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 507 | $2K |
| 86580 | <1% | 155 | $2K | |
| 92551 | <1% | 140 | $2K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 701 | $2K |
| G0466 | Community health center visit, new patient | <1% | 91 | $2K |
| 87581 | <1% | 64 | $2K | |
| 86708 | <1% | 133 | $2K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 95 | $1K |
| 86592 | <1% | 345 | $1K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 28 | $1K |
| 0154A | <1% | 27 | $1K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 347 | $1K |
| 99401 | <1% | 26 | $1K | |
| 82785 | <1% | 87 | $1K | |
| 86593 | <1% | 317 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 45 | $1K |
| 85014 | <1% | 541 | $1K | |
| 92015 | Determination of refractive state | <1% | 46 | $1K |
| 85018 | <1% | 539 | $1K | |
| 82465 | <1% | 272 | $1K | |
| 90710 | <1% | 170 | $1K | |
| 83021 | <1% | 56 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 258 | $1K |
| 99403 | <1% | 12 | $1K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 18 | $1K |
| H0049 | Alcohol and/or drug screening | <1% | 21 | $1K |
| 91320 | <1% | 15 | $980.28 | |
| 99173 | <1% | 76 | $788.90 | |
| 92083 | <1% | 12 | $760.70 | |
| 84436 | <1% | 121 | $649.16 | |
| D1206 | Topical application of fluoride varnish | <1% | 83 | $600.50 |
| 90661 | <1% | 81 | $561.49 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 14 | $560.03 |
| 87800 | <1% | 14 | $544.00 | |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | <1% | 57 | $527.80 |
| 90698 | <1% | 332 | $499.80 | |
| 92133 | <1% | 13 | $487.16 | |
| 84550 | <1% | 108 | $465.70 | |
| 90674 | <1% | 71 | $395.99 | |
| 90653 | <1% | 22 | $342.25 | |
| 90696 | <1% | 77 | $325.77 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 25 | $295.44 |
| 82570 | <1% | 50 | $292.50 | |
| 90744 | <1% | 50 | $285.95 | |
| 91319 | <1% | 64 | $210.21 | |
| 96160 | <1% | 17 | $145.38 | |
| 85651 | <1% | 43 | $143.21 | |
| 99381 | <1% | 63 | $132.62 | |
| 90658 | <1% | 79 | $129.70 | |
| 84479 | <1% | 25 | $79.18 | |
| 82550 | <1% | 14 | $76.21 | |
| 84460 | <1% | 12 | $72.61 | |
| 84450 | <1% | 12 | $72.61 | |
| 82947 | <1% | 12 | $48.19 | |
| 1159F | <1% | 1,460 | $45.00 | |
| 85041 | <1% | 42 | $42.25 | |
| 90681 | <1% | 28 | $35.70 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 137 | $33.18 |
| 94760 | <1% | 13 | $30.76 | |
| 81003 | <1% | 16 | $28.54 | |
| 90654 | <1% | 12 | $19.35 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 12 | $17.34 |
| 36406 | <1% | 12 | $12.26 | |
| 3077F | 0% | 1,624 | $0.00 | |
| 3078F | 0% | 8,707 | $0.00 | |
| 1160F | 0% | 954 | $0.00 | |
| 99499 | 0% | 656 | $0.00 | |
| 99080 | 0% | 18 | $0.00 | |
| 90685 | 0% | 19 | $0.00 | |
| 3080F | 0% | 502 | $0.00 | |
| 3079F | 0% | 2,502 | $0.00 | |
| 3075F | 0% | 2,758 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 27 | $0.00 |
| 1220F | 0% | 420 | $0.00 | |
| D0601 | 0% | 36 | $0.00 | |
| D0603 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.